Amendments to the Claims

Please cancel claims 11 and 31 without prejudice.

Please amend claims 8 and 29, as indicated in the Listing of Claims.

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-7 (Canceled)

8. (Currently Amended) A method of ameliorating an autoimmune disease or graft rejection in an animal, the method comprising administering to the animal a therapeutically effective amount of a monoclonal antibody having the specificity of the monoclonal antibody produced by ATCC HB 10160, wherein the antibody is capable of suppressing intercellular leukocyte-leukocyte adhesion, and wherein the antibody binds to an epitope on the leukocyte adhesion receptor β-chain, thereby ameliorating the autoimmune disease or graft rejection in the animal.

9. (Original) The method of claim 8, wherein the receptor is selected from the group consisting of LFA-1, Mac-1, and Leu M5.

Claims 10-11 (Canceled)

12. (Previously Presented) The method of claim 8, wherein the antibody is produced by hybridoma cell line ATCC HB 10160.

13. (Original) The method of claim 8, wherein the administration is parenteral.

14. (Original) The method of claim 13, wherein the parenteral administration is by subcutaneous, intramuscular, intraperitoneal, intracavity, transdermal, or intravenous injection.

15. (Original) The method of claim 8, wherein said administration is at a dosage of about 0.01 mg/kg/dose to about 2000 mg/kg/dose.

16. (Original) The method of claim 8, wherein the monoclonal antibody is therapeutically labeled.

17. (Original) The method of claim 16, wherein the therapeutic label is selected from the group consisting of a radioisotope, a drug, a lectin, and a toxin.

Claims 18-23 (Canceled)

24. (Previously Presented) A method of suppressing HIV-induced cell fusion, comprising:
contacting a leukocyte infected with HIV with an effective amount of an antibody, capable of suppressing intercellular leukocyte-leukocyte adhesion, wherein the antibody binds to an epitope on the leukocyte adhesion receptor β-chain, thereby suppressing HIV-induced cell fusion.

25. (Previously Presented): The method of claim 24, wherein the receptor is LFA-1.

26. (Previously Presented): The method of claim 24, wherein the monoclonal antibody has the specificity of the monoclonal antibody produced by ATCC HB 10160.

27. (Previously Presented) The method of claim 24, wherein the antibody is administered at a dosage of about 0.01 mg/kg/dose to about 2000 mg/kg/dose.

28. (Previously Presented): The method of claim 24, wherein the monoclonal antibody is therapeutically labeled.

29. (Currently Amended) A method of ameliorating graft rejection in an animal, the method comprising administering to the animal a therapeutically effective amount of an antibody having the specificity of the monoclonal antibody produced by ATCC HB 10160, capable of suppressing intercellular leukocyte-leukocyte adhesion, wherein the antibody binds to an epitope

on the leukocyte adhesion receptor β-chain, thereby ameliorating the graft rejection in the patient.

30. (Previously Presented) The method of claim 29, wherein the receptor is selected from the group consisting of LFA-1, Mac-1, and Leu M5.

31. (Canceled)

32. (Previously Presented) The method of claim 29, wherein said administration is at a dosage of about 0.01 mg/kg/dose to about 2000 mg/kg/dose.

33. (Previously Presented) The method of claim 29, wherein the monoclonal antibody is therapeutically labeled.

34. (Previously Presented) The method of claim 29, wherein the animal is a human.